[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360292-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-360292-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prevention-and-management-of-cardiovascular-disease-in-adults-with-cancer-an-international-cardio-oncology-society-ic-os-and-multinational-association-of-supportive-care-in-cancer-mascc-clinical-practice-statement","Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement","","Purpose: Cardiovascular (CV) toxicity is common among cancer survivors due to shared risk factors, direct cardiovascular injury from cancer therapy (CT), and worsening of CV risk during treatment. This clinical practice statement outlines a minimum standard of CV care for cancer care providers (CCPs) to improve survivor outcomes. It targets CCPs on identification, prevention, and management of cardiovascular disease (CVD) across the cancer trajectory. Methods: The International Cardio-Oncology Society and MASCC formed expert groups from oncology, cardiology, and survivorship; practice questions were mapped, literature reviewed, and consensus reached for recommendations.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prevention-and-management-of-cardiovascular-disease-in-adults-with-cancer-an-international-cardio-oncology-society-ic-os-and-multinational-association-of-supportive-care-in-cancer-mascc-clinical-practice-statement/360292/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prevention-and-management-of-cardiovascular-disease-in-adults-with-cancer-an-international-cardio-oncology-society-ic-os-and-multinational-association-of-supportive-care-in-cancer-mascc-clinical-practice-statement/360292.png","ImageObject",300,407,{"name":42,"@type":43},"Pentious","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is cardiovascular care needed for cancer survivors?","Question",{"text":63,"@type":64},"Cardiovascular toxicity is prevalent because cancer survivors share risk factors, experience direct cardiovascular injury from cancer therapy, and may develop or worsen cardiovascular risk factors during treatment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Who is the clinical practice statement intended for and what does it cover?",{"text":68,"@type":64},"It is aimed at cancer care providers who focus on identification, prevention, and management of cardiovascular disease in people with cancer across the treatment pathway.",{"name":70,"@type":61,"acceptedAnswer":71},"What are the key clinical practice recommendations for cancer care providers?",{"text":72,"@type":64},"Recommendations include CV risk assessment before starting cancer therapy, facilitating CV-related care during therapy, mitigating therapy-related CV toxicity before and during treatment, monitoring status and referring when risks are uncontrolled, and re-assessing CV risk after completing therapy with ongoing surveillance plans when needed.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},360292,1790302037,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Supportive Care in Cancer (2026) 34:590  \n[https://doi.org/10.1007/s00520-026-10741-8](https://doi.org/10.1007/s00520-026-10741-8)  \nPrevention and management of cardiovascular disease in adults with cancer: an International Cardio‑Oncology Society (IC‑OS)  \nand Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement  \nSusan Dent · Michelle B. Nadler · Anne Blaes · Ahamed Iqbal · Hannah Naa Gogwe Ayettey · Jose Alvarez‑Cardona, et al. [full author details at the end of the article]  \nReceived: 9 March 2026 / Accepted: 6 April 2026 / Published online: 29 May 2026 © The Author(s) 2026, modified publication 2026  \nAbstract  \nPurpose Cardiovascular (CV) toxicity is prevalent in cancer survivors due to shared risk factors, direct CV injury from cancer therapy (CT), and development/exacerbation of CV risk factors during treatment. Succinct guidance on the minimum standard of CV care required of cancer care providers (CCPs) can improve outcomes for survivors. This clinical practice statement (CPS) is aimed at CCPs focused on identification, prevention, and management of CVD in individuals with cancer. Methods The International Cardio-Oncology Society and Multinational Association of Supportive Care in Cancer identified members with expertise across oncology, cardiology, and cancer survivorship. Key questions/areas of practice recommendations related to CV risk and CVD were identified across the cancer trajectory.Working groups performed targeted literature reviews and consensus was reached for all recommendations.  \nResults 5 over-arching clinical practice recommendations for CCPs were identified: (1) perform a CV risk assessment prior to starting CT (2) identify and facilitate CV-related care during CT; (3) ensure measures are taken to mitigate the risk of cancer therapy related CV toxicity (CTR-CVT) prior to and during CT; (4) monitor CV status and risk factors during therapy and refer to the appropriate health care provider if CV risk factors are uncontrolled or new signs/symptoms develop; and (5) re-assess CV risk following completion of CT (periodically for those with advanced disease on life long treatment) and develop a CV surveillance plan.  \nConclusions CCPs play a pivotal role in identifying and addressing CTR-CVT. This CPS provides specific, succinct, and actionable behaviours that can be readily implemented in cancer care globally.  \nThis publication was approved by both the International CardioOncology Society and the Multinational Association of Supportive Care in Cancer and it has been peer-reviewed. It is published simultaneously in Supportive Care in Cancer ([https://doi.org/10](https://doi.org/10) . 1007/s00520-026-10741-8) and Cardio-Oncology ([https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.1007/s00520-026-10741-8](10.1007/s00520-026-10741-8)) .  \nGraphical Abstract  \nKeywords Cancer survivorship · Cardiovascular toxicity · Prevention · Management · Multidisciplinary care  \nDisclaimer  \nThe Multinational Association of Supportive Care in Cancer (MASCC) and International Cardio-Oncology Society (ICOS) Clinical Practice Statement (CPS) has been developed to facilitate expert-opinion-based recommendations, for cancer care professionals, on the minimum standard of care for cardiovascular risk assessment and management in individuals with cancer. Clinicians should use their judgment when making treatment decisions for individual patients. Statements made by the authors and the MASCC/ICOS organizations do not guarantee clinical outcomes in individual patients.  \nIntroduction  \nCardiovascular (CV) disease is a major competing cause of mortality and morbidity in cancer survivors [1 , 2] given the improvements seen in survivorship largely due to early detection and improved cancer therapies [3, 4] . CV toxicity can occur due to the direct impact of cancer therapy on the CV system or indirectly by negatively impacting risk factors for CVD [5 , 6] . Furthermore, identification, ","cbCaicXif8XElQlb","https://ap.wps.com/l/cbCaicXif8XElQlb","pdf",1099136,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Background and burden of CV disease in cancer survivorship\n## Need for guidance for cancer care providers","[{\"question\":\"Why is cardiovascular care needed for cancer survivors?\",\"answer\":\"Cardiovascular toxicity is prevalent because cancer survivors share risk factors, experience direct cardiovascular injury from cancer therapy, and may develop or worsen cardiovascular risk factors during treatment.\"},{\"question\":\"Who is the clinical practice statement intended for and what does it cover?\",\"answer\":\"It is aimed at cancer care providers who focus on identification, prevention, and management of cardiovascular disease in people with cancer across the treatment pathway.\"},{\"question\":\"What are the key clinical practice recommendations for cancer care providers?\",\"answer\":\"Recommendations include CV risk assessment before starting cancer therapy, facilitating CV-related care during therapy, mitigating therapy-related CV toxicity before and during treatment, monitoring status and referring when risks are uncontrolled, and re-assessing CV risk after completing therapy with ongoing surveillance plans when needed.\"}]","Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement | PDF",1790139507,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14507fcd18ba545ed0b690e80258c273.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/015cb73e9ebcc3de44278847118587e8.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3cb275cb13816fa4aff2a1524c9685f7.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64c32cedf5aa7ebf7545e79fe8cf9bb3.webp",980,1301]